CTLA4 and melanoma: Of note, Jacquelot et al. reported that melanoma patients who got clinical benefits from ipilimumab (CTLA-4 inhibitor) had lower positivity of PD-L1 on CD8 T cells than whoever did not get clinical benefits from ipilimumab (31).